CLAIM AMENDMENTS

This listing of claims will replace all prior versions and listings of claims in the application:

1. **(currently amended)** A pharmaceutical composition comprising a salt, **wherein** the salt **comprises:** ~~comprising~~

an organic acid having low water solubility, and

a compound of formula (I):





(I);

[[where]]

R^1, R^2, and R^3 are **independently** ~~the same or different and are:~~ -H, C$_1$-C$_6$ alkyl, C$_3$-C$_5$ alkenyl, C$_3$-C$_5$ alkynyl, C$_3$-C$_5$ cycloalkyl, C$_4$-C$_{10}$ cycloalkyl, phenyl substituted **or** C$_1$-C$_6$ alkyl ~~,~~ ~~-NR$_1$R$_2$ where R$_1$ and R$_2$ are cyclized with the attached nitrogen atom to produce pyrrolidiyl, piperidinyl, morphoninyl, 4-methyl piperazinyl or imidazolyl~~;

X is [[:]] -H, C$_1$-C$_6$ alkyl, -F, -Cl, -Br, -I, -OH, C$_1$-C$_6$ alkoxy, cyano, carboxamide, carboxyl, **or** (C$_1$-C$_6$ alkoxy)carbonyl;

A is [[:]] CH, CH_2, **CHCl, CHF, CHBr, CHI,** ~~CH-(halogen) (where halogen is Cl, F, Br, or I),~~ $CHCH_3$, C=O, C=S, C-SCH_3, C=NH, C-NH_2, C-$NHCH_3$, C-$NHCOOCH_3$, **or** C-NHCN ~~, SO_2, N~~;

~~B is: CH_2, CH, CH-(halogen) where halogen is as defined above, C=O, N, NH, N-CH_3,~~

Z [[D]] is ~~: CH, CH_2, CH-(halogen) where halogen is as defined above, C=O, O,~~ N, NH, **or** N-CH_3; ~~and n is 0 or 1, and where~~

the structure ⋯ is a single or double bond**;** ~~, with the provisos: (1) that~~

when ~~n is 0, and~~ A is CH_2, **CHCl, CHF, CHBr, CHI,** ~~CH-(halogen) where halogen is as defined above,~~ $CHCH_3$, C=O, C=S, C=NH, [[SO_2;]] then **Z** [[D] is ~~CH_2, CH-(halogen) where halogen is as defined above, C=O, O,~~ NH [[,]] N-CH_3; **and** ~~(2) that~~

when ~~n is 0, and~~ A is CH, C-SCH_3, C-NH_2, C-$NHCH_3$, C-$NHCOOH_3$, **or** C-NHCN, [[N;]] then **Z** [[D]] is [[CH,]] N ~~;~~

~~(3) that when n is 1, and~~

~~A is CH_2, CH-(halogen) where halogen is as defined above, $CHCH_3$, C=O, C-S , C=NH, SO_2; and~~

~~B is CH_2, CH-(halogen) where halogen is as defined above, C=O, NH, N-CH_3; then~~

~~D is CH_2, C=O, O, NH, N-CH_3;~~

~~(4) that when n is 1, and~~

~~A is CH, C-SCH_3, C-NH_2, C-$NHCH_3$, C-$NHCOOCH_3$, C-NHCN, N; and~~

~~B is CH, N; then~~

~~D is CH_2, C=O, O, NH, N-CH_3;~~

~~(5) that when n is 1, and~~

~~A is CH_2, $CHCH_3$, C=O, C=S, C=NH, SO_2, and~~

~~B is CH, N; then~~

~~D is CH, N~~.

2. **(currently amended)** A composition according to claim 1, wherein the organic acid has a water solubility of **no greater than** about 0.1% (w/w) ~~or less~~.

3. **(original)** A composition according to claim 1, wherein:

the organic acid is a compound selected from the group consisting of $CH_3(CH_2)_nCOOH$, $HOOC(CH_2)_mCOOH$,



(A), and



(B);

R_1, R_2, and R_3 are independently selected from the group consisting of hydroxy, amino, and nitro;

n is an integer from 5 to 16; and

m is an integer from 5 to 16.

4. **(original)** A composition according to claim 3, wherein the organic acid is pamoic acid.

5. **(original)** A composition according to claim 3, wherein the organic acid is xinafoic acid.

6. **(currently amended)** A composition according to claim 1, wherein the compound is selected from the group consisting of sumanirole, (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1H)-thione, and (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-*ij*]quinolin-5-amine.

7. **(original)** A composition according to claim 5, wherein the compound is sumanirole.

8. **(currently amended)** A composition according to claim 1, wherein the salt has a dissolution rate into aqueous solution of **no greater than** about 0.40 mmole $sec^{-1}cm^{-2}$ ~~or less~~.

9. **(currently amended)** A composition according to claim 8, wherein the salt has a dissolution rate into aqueous solution of **no greater than** about 0.05 mmole sec^{-1}cm^{-2} ~~**or less**~~.

Claims 10-48 (canceled).

49. **(withdrawn - currently amended)** A method of treating Parkinson's disease in a mammal in need thereof, **wherein** the method **comprises** ~~**comprising**~~ administering to the mammal a therapeutically effective amount of a **pharmaceutical** composition **recited in claim 1** ~~**comprising a salt, the salt comprising:**~~

~~**an organic acid having low water solubility; and**~~

~~**a compound of formula (I)**~~



~~**where**~~

~~**R^1, R^2 and R^3 are the same or different and are: -H, C$_1$-C$_6$ alkyl, C$_3$-C$_5$ alkenyl, C$_3$-C$_5$ alkynyl, C$_3$-C$_5$ cycloalkyl, C$_4$-C$_{10}$ cycloalkyl, phenyl substituted C$_1$-C$_6$ alkyl, -NR$_1$R$_2$ where R$_1$ and R$_2$ are cyclized with the attached nitrogen atom to produce pyrrolidiyl, piperidinyl, morphoninyl, 4-methyl piperazinyl or imidazolyl;**~~

~~**X is: -H, C$_1$-C$_6$ alkyl, -F, -Cl, -Br, -I, -OH, C$_1$-C$_6$ alkoxy, cyano, carboxamide, carboxyl, (C$_1$-C$_6$ alkoxy)carbonyl;**~~

~~**A is: CH, CH$_2$, CH-(halogen) (where halogen is Cl, F, Br, or I), CHCH$_3$, C=O, C=S, C-SCH$_3$, C=NH, C-NH$_2$, C-NHCH$_3$, C-NHCOOCH$_3$, C-NHCN, SO$_2$, N;**~~

~~**B is: CH$_2$, CH, CH-(halogen) where halogen is as defined above, C=O, N, NH, N-CH$_3$;**~~

~~**D is: CH, CH$_2$, CH-(halogen) where halogen is as defined above, C=O, O, N, NH, N-CH$_3$; and n is 0 or 1, and where ┈ is a single or double bond, with the provisos:**~~

~~(1) that when n is 0, and~~

~~A is CH_2, CH-(halogen) where halogen is as defined above, $CHCH_3$, C=O, C=S, C=NH, SO_2; then~~

~~D is CH_2, CH-(halogen) where halogen is as defined above, C=O, O, NH, N-CH_3;~~

~~(2) that when n is 0, and~~

~~A is CH, C-SCH_3, C-NH_2, C-$NHCH_3$, C-$NHCOOH_3$, C-NHCN, N; then D is CH, N;~~

~~(3) that when n is 1, and~~

~~A is CH_2, CH-(halogen) where halogen is as defined above, $CHCH_3$, C=O, C-S , C=NH, SO_2; and~~

~~B is CH_2, CH-(halogen) where halogen is as defined above, C=O, NH, N-CH_3; then~~

~~D is CH_2, C=O, O, NH, N-CH_3;~~

~~(4) that when n is 1, and~~

~~A is CH, C-SCH_3, C-NH_2, C-$NHCH_3$, C-$NHCOOCH_3$, C-NHCN, N; and~~

~~B is CH, N; then~~

~~D is CH_2, C=O, O, NH, N-CH_3;~~

~~(5) that when n is 1, and~~

~~A is CH_2, $CHCH_3$, C=O, C=S, C=NH, SO_2, and~~

~~B is CH, N; then~~

~~D is CH, N.~~

50. **(withdrawn - currently amended)** A method according to claim 49, wherein the organic acid has a water solubility of **no greater than** about 0.1% (w/w) ~~or less~~.

51. **(withdrawn)** A method according to claim 50, wherein:

the organic acid is a compound selected from the group consisting of $CH_3(CH_2)_nCOOH$, $HOOC(CH_2)_mCOOH$,



(A), and



(B);

R_1, R_2, and R_3 are independently selected from the group consisting of hydroxy, amino, and nitro;

n is an integer from 5 to 16; and

m is an integer from 5 to 16.

52. **(withdrawn)** A method according to claim 51, wherein the organic acid is selected from the group consisting of pamoic acid and xinafoic acid.

53. **(withdrawn)** A method according to claim 49, wherein the compound is selected from the group consisting of sumanirole, (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1H)-thione and (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-*ij*]quinolin-5-amine.

54. **(withdrawn)** A method according to claim 53, wherein the compound is sumanirole.

55. **(withdrawn - currently amended)** A method according to claim 49, wherein the salt has a dissolution rate into aqueous solution of **no greater than** about 0.40 mmole $sec^{-1}cm^{-2}$ ~~or less~~.

56. **(withdrawn - currently amended)** A method according to claim 55, wherein the salt has a dissolution rate into aqueous solution of **no greater than** about 0.05 mmole $sec^{-1}cm^{-2}$ ~~or less~~.

57. **(withdrawn)** A method according to claim 49, wherein the administering is orally administering.

58. **(withdrawn)** A method according to claim 49, wherein the mammal is a human.

59. **(withdrawn)** A method according to claim 58, wherein the administering is no more often than about twice daily.

60. **(withdrawn)** A method according to claim 58, wherein the administering is no more often than about once daily.

61. **(withdrawn)** A method according to claim 49, wherein the therapeutically effective amount is from about 2 mg per day to about 120 mg per day.

62. **(withdrawn)** A method according to claim 61, wherein the therapeutically effective amount is from about 3 mg per day to about 70 mg per day.